SKYTROFA® is the first FDA‑approved once‑weekly treatment for pediatric GHD that offers:

  • Up to 86% fewer injections per year compared with daily therapies1,2
  • No refrigeration required for up to 6 months1
  • Higher LS mean annualized height velocity (AHV) at week 52 in a clinical trial1,3*

Treatment difference in LS mean AHV of 0.9 cm/year (11.2 cm/year for SKYTROFA compared with 10.3 cm/year for a daily somatropin) with 95% CI: 0.2 to 1.5 cm/year

* In the heiGHt trial, a phase 3 study comparing once-weekly SKYTROFA with a daily somatropin, both administered subcutaneously in 161 treatment-naïve children with GHD. The primary endpoint was LS mean AHV at week 52.1,3